Algomedix Is An Emergingbiotechnology Company Which Is Using The Advances In Precision Medicine To Accelerate Drug Discovery And Development For Trptransient Receptor Potentialtargeted Therapeutics Critical Members Of The Large Trp Superfamily Include Trpa1Which Is A Validated Target Recognized By The Pharmaceutical Industry For The Discovery And Development Of Novel Therapeutics To Treat Paininflammationocular And Dermatological Disease Algomedix Has Successfully Identified Novel Small Molecules That Target Human Trpa1 With Both High Potency And Specificityand Have Been Optimized To Have Excellent Drug Like Properties Thusthe Algomedix Compounds Represent A Major Advance In Next Generation Pain Killers Which Have No Opioid Relatednsaid Relatedor Gabapentanoid Adverse Effectsand Have Been Rationally Designed To Have No Addiction Or Abuse Liabilities These Advantages Are Further Enhanced By A Primary Peripheral Mechanism Of Actionblocking Pain At Its Source Algomedix Possesses Near Term Clinical Development Opportunities Combined With Novel Approaches To Developing Its First In Class Novel Therapeutics Addressing A Critical Unmet Medical Need Algomedix S Most Advanced Patented Compound Is In Late Stage Preclinical Development And Prepared To Advance To Clinical Trialsthis Compound Has Demonstrated Potent Analgesic Activity Activity In Multiple Established Pain Modelswhich Are Recognized As The Gold Standards In The Areas Of Osteoarthritis Painoa Neuropathic Painand Chemotherapeutic Induced Peripheral Neuropathy Due To The Critical And Fundamental Role Of Trpa1 In Mediating The Initial Steps Of Pain Signaling Throughout The Bodythere Are Multiple Therapeutic Applications For Treating Chronic And Acute Pain In Patients In Additionalgomedix Is Pursuing Programsdeveloping A Pipeline Of Novelfirst In Class Molecules For Other Indicationswhich Include Chronic Kidney Disease And Cardiac Hypertrophy
